Fujifilm Announces Financial Results for the First Half Ended September 30, 2026

In the second quarter, the three months ended September 30, 2026, Fujifilm achieved record-high revenue, operating income and net income attributable to FUJIFILM Holdings supported by strong sales of endoscopes in Healthcare segment, semiconductor materials and data tapes in Electronics segment, and instax^™ products in Imaging segment, while continuing to improve profitability in the Bio CDMO business and strengthening the operational foundation of the Business Innovation segment.

"We continue to capture robust demand across our growth businesses and deliver solid growth across the Company. As we enter the final six months of our current medium-term management plan, VISION2030, we will remain firmly focused on delivering results, while executing the necessary reforms and establishing a clear path toward our next medium-term management plan," says Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Holdings Corporation.